Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary Crocker acquired 17,500 shares of the company’s stock on the open market in a transaction dated Tuesday, May 6th. The stock was purchased at an average price of $6.89 per share, with a total value of $120,575.00. Following the acquisition, the director now directly owns 2,783,271 shares in the company, valued at approximately $19,176,737. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) weekly performance is 3.89%. On last trading day company shares ended up $6.68. Analysts mean target price for the company is $10.90. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 25.48%.
Aegerion Pharmaceuticals Inc (NASDAQ:AEGR) Director Anne Vanlent purchased 4,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average cost of $33.78 per share, with a total value of $135,120.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $135,120. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares fell -1.12% in last trading session and ended the day on $32.62. Gross Margin is 89.70% and its return on assets is-45.10%. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) quarterly performance is -47.53%.
BioTime Inc (NYSE:BTX) Director Broadwood Partners Lp acquired 300,000 shares of the company’s stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average price of $2.44 per share, for a total transaction of $732,000.00. The acquisition was disclosed in a document filed with the SEC. BioTime also was the target of a large increase in short interest in April. As of April 30th, there was short interest totalling 4,066,791 shares, an increase of 2.1% from the April 15th total of 3,982,909 shares. Based on an average trading volume of 151,420 shares, the days-to-cover ratio is currently 26.9 days. BioTime, Inc. (NYSEMKT:BTX)ended the last trading day at $2.35 . Company weekly volatility is calculated as 9.53% and price to cash ratio as 29.75. BioTime, Inc. (NYSEMKT:BTX) showed a negative weekly performance of -3.29%.
Leave a Reply